Dr. Daipayan Banerjee

Qualification B.Tech., Ph.D.
Designation Scientist 1
Aravind Medical Research Foundation
e-mail id daipayan@aravind.org

Dr. Daipayan Banerjee completed his Bachelor’s of Technology degree in Biotechnology from Bengal College of Engineering and Technology/ West Bengal University of Technology (WBUT) in 2005. He obtained his PhD in Biology (Molecular Biology) from the University of Kentucky, USA in 2013.

Daipayan did his first postdoctoral training in the University of Kentucky Medical School, Physiology Department (2013-2015)where he studied inflammatory mediators in aging. His second postdoctoral training was in the Department of Ophthalmology and Visual Sciences, University of Kentucky where he studied the role of the inflammasome in age-related macular degeneration (AMD). In 2016, he moved to the University of Virginia, Center for Advanced Vision Sciences where he continued his study on AMD pathogenesis. He has joined the Aravind Medical Research Foundation in September 2020.

While in the Center of Advanced Vision Sciences, University of Virginia, he investigated how retinal pigmented epithelium (RPE) cell death occur in Geographic atrophy, a blinding and untreatable form of age-related macular degeneration.

Daipayan’s current research interests entail understanding the molecular mechanism of pterygium progression, a highly prevalent condition in tropical region that is characterized by a benign conjunctiva overgrowth protruding towards the cornea thus affecting vision and quality of life. In the absence of pharmacological intervention, surgical excision is the only available medical intervention. The broad objective is to identify pathways that can be targeted to impede pterygium progression.

Daipayan is also interested in studying the mechanism of diabetic retinopathy (DR), a progressive retinal disorder which is a diabetic complication that can result in blindness and affects millions of people in India. Currently, there is no predictive tool to prognosticate if a diabetic person will develop DR, or if a person develops non-proliferative DR, other than dietary changes, there is no pharmaceutical intervention to prevent developing advanced proliferative DR. The broad objective is to developing prognostic and intervention tools.

Key Publications:

  1. Cytoplasmic synthesis of endogenous Alu complementary DNA via reverse transcription and implications in age-related macular degeneration, Shinichi Fukuda, AkhilVarshney, Benjamin J. Fowler…..Daipayan Banerjee…Bradley D. Gelfand, Fred H. Gages, JayakrishnaAmbati, PNAS, 2021.
  2. cGAS drives noncanonical-inflammasome activation in age-related macular degeneration, NagarajKerur, Shinichi Fukuda, Daipayan Banerjee et al, Nature Medicine, 2018.